CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: management transactions · United States · SEC (Form 4)

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc. (NYSE: CRL) is a U.S.-based company listed on the NYSE in the United States and is widely recognized as a global partner to pharmaceutical, biotechnology, government, and academic customers in accelerating research and drug development. Headquartered in Wilmington, Massachusetts, the company traces its operating roots back to 1947, while the current corporate entity was incorporated in 1994 and completed its IPO in 2000. Over time, Charles River has built a reputation as a highly specialized “picks-and-shovels” provider for the life sciences industry, supplying mission-critical research tools and outsourced services rather than marketed therapeutics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1100682/000110068224000007/crl-20231230.htm?utm_source=openai)) The company’s business is organized around three core segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. RMS provides research models, laboratory animals, and related services. DSA spans drug discovery support, pharmacology, toxicology, pathology, and regulatory-oriented testing services that help advance candidates through preclinical development. Manufacturing Solutions supports customers with manufacturing-related capabilities and advanced therapy development, including cell and gene therapy-adjacent services. This mix gives Charles River broad exposure across the drug-development value chain and creates multiple touchpoints with both large pharmaceutical companies and smaller biotech innovators. ([ir.criver.com](https://ir.criver.com/?utm_source=openai)) From a competitive standpoint, Charles River stands out through its scientific depth, global footprint, and integrated offering. It occupies a strong position in preclinical research and safety assessment, areas where regulatory rigor and technical expertise create meaningful barriers to entry. The company has also emphasized digital and AI-enabled capabilities, including digital pathology workflows, to improve study timelines and operational productivity. That evolution is important because customers are increasingly looking for faster, more efficient, and more data-rich development processes. ([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-accelerates-digital-pathology-ai-powered-end-end?utm_source=openai)) Geographically, Charles River serves clients across major life-science markets worldwide, with a meaningful presence in North America, Europe, and Asia. Recent company developments highlight a strategy focused on innovation, partnerships, and advanced modalities: it extended a long-running Huntington’s disease research collaboration with CHDI Foundation, expanded cell and gene therapy initiatives, and announced continued momentum in its AI-enabled digital pathology platform. These developments support the company’s long-term positioning, although results remain exposed to R&D spending cycles in pharma and biotech. ([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-and-chdi-foundation-extend-multi-decade/?utm_source=openai))